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Introduction 
Conflicting results have been published on the in- 
fluence of metabolites occurring during phenylketo- 
nuria on the activity of the pyruvate dehydrogenase 
multienzyme complex. Inhibition of the brain enzyme 
by phenylpyruvate has been reported [l] but could 
not be confirmed by others [2,11]. Neither investiga- 
tion included the effect of the respective metabolites 
on the rate of the interconversion of the pyruvate de- 
hydrogenase from its active nonphosphorylated to 
its inactive phosphorylated form [3,4]. This inter- 
conversion appears to be under control by metabo- 
lites of low molecular weight, e.g. pyruvate, ATP, 
ADP [5,6]. Therefore we investigated the effect of 
a variety of metabolites involved in phenylketonuria 
on the pyruvate dehydrogenase kinase and phospha- 
tase activity. We show in the present paper that 
phenylpyruvate influences the rate of interconver- 
sion of the pyruvate dehydrogenase complex from 
its active to the non-active form, i.e. it inhibits 
phosphorylation of the complex by the pyruvate 
dehydrogenase kinase. None of the compounds tested 
had any effect on the enzyme directly, i.e. by 
competitive inhibition or activation. With respect 
to phenylpyruvate, no significant qualitative difference 
was found for the kidney and the brain enzymes. 
At this stage of the investigation, the bearing of these 
findings on the interpretation of the symptoms of 
the disease isnot clear, but they are pertinent o our 
understanding of the mechanism of the interconver- 
sion of the pyruvate dehydrogenase complex. Togeth- 
er with earlier esults [4-61, they are indicative 
of a regulatory o-ketoacid binding site on the protein 
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separate from the active center substrate binding 
site. 
2. Materials 
Nti, thiamine pyrophosphate and sodium pyru- 
vate were obtained from Boehringer und Soehne, 
Germany; coenzyme A and dithiothreitol were from 
Serva, Germany. Substances used as effecters were 
as follows: sodium salts of phenylpyruvic acid (Fltia, 
Switzerland), L-phenylalanine and indole3-acetic 
acid (Merck, Germany), L-3-phenyllactic acid and 
o-hydroxy-phenylacetic a id (EGA-Chemie, Germany), 
and DL3-indolelactic acid (Aldrich, USA). 
3. Methods 
3.1. Atrification procedures 
The preparation of the enzyme from bovine kidney 
mitochondria was basically the same as described by 
Linn et al. [7] , but without the ultimate steps of 
ultracentrifugation a d acid precipitation. Bovine brain 
mitochondria were prepared by the method of Burgett 
[8]. Here too, the ultracentrifugation a d acid 
precipitation steps were omitted. The mitochondrial 
preparations were subjected to 4 X 30 set sonifica- 
tion instead of being homogenized in a Manton- 
Gaulin-homogenizer. The specific activity of the 
kidney pyruvate dehydrogenase complex was 1.4 
moles NADH/min/mg protein at 25”C, while the 
specific activity of the brain pyruvate dehydroge- 
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nase complex was 0.4 moles NADH/min/mg pro- 
tein at 25’C. 
3.2. Assay of pyruvate dehydrogenase complex 
The standard assay procedure was the same as 
described elsewhere [7]. The temperature was 30°C. 
The reaction was initiated by addition of enzyme. 
3.3. Assay of pyruvate dehydrogenase kinase 
The pyruvate dehydrogenase kinase activity of 
the pyruvate dehydrogenase complex was determi- 
ned by measuring the decrease of activity of the 
enzyme complex in the presence of ATP. 
3.4. Assay of pyruvate dehydrogenase phosphatase 
The assay is based on the reactivation of an in- 
activated (i.e. phosphorylated) preparation of the 
pyruvate dehydrogenase complex by the phosphatase. 
4. Results 
4.1. Effect of metabolites on the activity of the pyru- 
vate dehydrogenase complex, pyruvate dehydro- 
genase kinase and pyruvate dehydrogenase 
phosphatase 
LPhenylalanine, indole-3-acetic acid, L3-phenyl- 
lactic acid, and phenylpyruvate were tested as to their 
effects on the phosphorylation and dephosphorylation 
of the kidney pyruvate dehydrogenase complex. Only 
phenylpyruvate inhibited the phosphorylation of the 
pyruvate dehydrogenase complex with increased con- 
centrations, as shown in fig. 2A, whereas the dephosp 
horylation of the pyruvate dehydrogenase complex was 
not significantly influenced by any of the effecters. 
Kinetic studies were undertaken to investigate the In view of the above results, the protective ffect 
effect of metabolites on the pyruvate dehydrogenase of phenylpyruvate on the activity of the brain pyruvate 
activity of bovine kidney. The method of Lineweaver dehydrogenase complex was investigated. Here too, the 
and Burk [9] was used to determine the influence of investigation showed (fig. 2B) that the phosphorylation 
the following substances on the activity of the kidney of the enzyme complex was inhibited to about the 
pyruvate dehydrogenase complex: phenylpyruvic 
acid, L-phenylalanine, indole-3-acetic acid, L-3.phenyl- 
lactic acid, Dl-3-indole-lactic acid and o-hydroxy-phe- 
nylacetic acid. Of the six metabolites tested, none 
was significantly inhibitory. However, increased con- 
centrations of phenylpyruvate (10 mM) showed the 
possibility of an uncompetitive inhibition (fig. 1 A), 
Brain pyruvate dehydrogenase complex activity 
was, therefore, investigated to determine if there was 
any influence due to phenylpyruvate and, here too, 
a 10 mM concentration of the effector showed an 
uncompetitive inhibition (fig. 1 B). Yet, since the 
highest recorded phenylpyruvate concentration i  
tissue [IO] is very much below this magnitude, it is 
unlikely that, in phenylketonuria, phenylpyruvate 
has any direct effect on the pyruvate dehydrogenase 
activity. 
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Fig, la and lb. PyIuvate dehydrogenase complex activity in the presence of phenylpyruvate. The initial rate. of activity was assa- 
yed in the presence of(d) 16 mM and (0) without phenylpyruvate. The standard assay at 30°C was as described in ‘Methods’. The 
reaction mixture contained a protein concentration of 25 &ml (kidney) and 39 &ml (brain). a: kidney pyruvate dehydrogenase 
complex. b: brain pyruvate dehydrogenase complex. 
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and dehydrogenase complex by pyruvate dehydro- 
genase kinase. Pyruvate dehydrogenase complex was incubated with 0.01 mM ATP (kidney) and 0.1 mM ATP (brain) at room tem- 
perature. ATP was omitted from the control. The reaction mixture contained 20 mM phosphate buffer, pH 7.0; 2 mM dithio- 
threitol; 0.2 mM MgCl,; and phenylpyruvate with the following concentrations: (0) 2 mM, (v) 5 mM, (0) JO mM, and (A) 20 mM; 
(0) contains no phenylpyruvate. At the time indicated 50 ~1 aliquots were removed and assayed under standard conditions. 
a: kidney pyruvate dehydrogenase complex; b: brain pyruvate dehydrogenase complex. 
same extent as the kidney enzyme, while the dephospo- 
rylation of the brain pyruvate dehydrogenase com- 
plex was not significantly affected (fig. 3). 
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Fig. 3. Reactivation of brain pyruvate dehydrogenase com- 
plex by pyruvate dehydrogenase phosphatase. Brain pyru- 
vate dehydrogenase complex was incubated at room tempe- 
rature with 0.1 mM ATP and the reaction mixture as des- 
cribed in the legend of fig. 2. At 85% inactivation by pyru- 
vate dehydrogenase kinase the incubation mixture was di- 
vided into two parts. To one part phenylpyruvate was added, 
while the other half was assayed without phenylpyruvate. 
Reactivation by pyruvate dehydrogenase phosphatase was 
started by adding MgCl, (arrow) to a final concentration 
of 10 mhI. At the time indicated, 50 ~1 aliquots were remo- 
ved and assayed under standard conditions. (0) without 
phenylpyruvate; ( 0) 10 mM phenylpyruvate. 
5. Discussion 
The experiments presented here lead to the follo- 
wing conclusions: 
1. Phenylpyruvate inhibits the interconver- 
sion of the pyruvate dehydrogenase complex 
from the active non-phosphorylated to the 
inactive phosporylated form. Other metabo- 
lites occurring during phenylketonuria (L- 
phenylalanine, indole-3-attic acid, L-3-phe- 
nylactic acid. DL-3-indole-lactic acid 
and o-hydroxy-phenyl-acetic acid) had no 
significant effect. 
2. The reverse reaction, the interconversion 
from the inactive to the active form, is not 
significantly affected by phenylpyruvate. 
3. Phenylpyruvate does not influence the acti- 
vity of the component enzymes of the mul- 
tienzyme complex directly, i.e. it does not 
compete with the substrate for the active 
site. 
4. The results with the pyruvate dehydrogenase 
complex isolated from mammalian brain and 
kidney are qualitatively the same. 
With these results it remains very doubtful if 
changes in the pyruvate dehydrogenase complex 
activity caused by elevated concentrations of 
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certain metabolites during phenylketonuria can 
be responsible for the observed symptoms. At 
present it is not clear how a shift of the enzyme 
to its active non-phosporylated state in vivo can 
cause for example the deficiency in myelin de- 
position in the nervous tissue which is characte- 
ristic for the disease. 
The effect of phenylpyruvate reported here, 
may have, on the other hand, important impli- 
cations for the enzymology of the pyruvate de- 
hydrogenase complex and the mechanism of its 
interconversion. We reported elsewhere a strong 
inhibition of the interconversion by pyruvate 
(for a discussion of possible physiological impli- 
cations of this effect lsee ref. [6] ). From various 
lines of evidence, we postulated that the binding 
site of the pyruvate which protects the multienzyme 
complex against phosphorylation and concomitant 
inactivation, is not identical with the binding site 
of the substrate pyruvate, i.e. we proposed that 
there is a regulatory pyruvate binding site. The data 
presented here now indicate that phenylpyruvate 
does not compete for the substrate binding site, 
because it is neither substrate nor competitive in- 
hibitor, but, like pyruvate, it still protects the com- 
plex against inactivation. 
The binding site for this protective molecule 
could be located on the pyruvate dehydrogenase 
kinase, the enzyme which catalyses the phosphory- 
lation and inactivation of the complex. But for the 
protective pyruvate we have shown no competition 
with ATP for the active site of the kinase [5]. To- 
gether with the results reported in this paper, these 
experiments may indicate that the pyruvate dehy- 
drogenase contains a separate regulatory site which 
is involved in the inactivation of the enzyme by 
phosphorylation and which binds protective mole- 
cules as pyruvate or phenylpyruvate. Further expe- 
riments are in progress to substantiate this conclu- 
sion. 
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